Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
HAEMATO AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €14.25 |
52 Week High | €20.80 |
52 Week Low | €13.90 |
Beta | 1.29 |
11 Month Change | -8.06% |
3 Month Change | -12.58% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -31.49% |
Recent News & Updates
Recent updates
Shareholder Returns
HAEK | DE Healthcare | DE Market | |
---|---|---|---|
7D | 1.1% | -3.0% | -1.0% |
1Y | n/a | 26.3% | 16.1% |
Return vs Industry: Insufficient data to determine how HAEK performed against the German Healthcare industry.
Return vs Market: Insufficient data to determine how HAEK performed against the German Market.
Price Volatility
HAEK volatility | |
---|---|
HAEK Average Weekly Movement | 2.8% |
Healthcare Industry Average Movement | 3.8% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.9% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HAEK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: HAEK's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 76 | Patrick Brenske | www.haemato.ag |
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements.
HAEMATO AG Fundamentals Summary
HAEK fundamental statistics | |
---|---|
Market cap | €74.49m |
Earnings (TTM) | €9.61m |
Revenue (TTM) | €260.81m |
7.8x
P/E Ratio0.3x
P/S RatioIs HAEK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HAEK income statement (TTM) | |
---|---|
Revenue | €260.81m |
Cost of Revenue | €241.08m |
Gross Profit | €19.73m |
Other Expenses | €10.12m |
Earnings | €9.61m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 1.84 |
Gross Margin | 7.56% |
Net Profit Margin | 3.68% |
Debt/Equity Ratio | 0.2% |
How did HAEK perform over the long term?
See historical performance and comparison